Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
Protecting a Way of Life in Haiti | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is helping to protect a way of life in Haiti by producing a custom swine vaccine to support the island.
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Real-world data announced for adults with type 2 diabetes
Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult